Clinical Trials - May 16, 2019
Disappointing trial results from Modus Therapeutics
The company announces initial results from its Phase II, randomized, double-blind, placebo-controlled study with sevuparin for the management of acute vaso-occlusive crisis (VOC) in patients with sickle cell disease. Data from the study failed to show a meaningful benefit in the total study population, however, the data suggests that sevuparin, at the administered doses, is […]
Business article - March 6, 2019
Company in focus: Modus Therapeutics
Swedish drug development company Modus Therapeutics has had a busy year, and 2019 could take them one step closer to having sevuparin on the market. In 2016 the clinical-stage drug development and Karolinska Development portfolio company Dilaforette Holding changed its name to Modus Therapeutics Holding. The move signified the company’s emancipation from its parent company […]
Clinical Trials - March 6, 2019
First cohort dosed in Modus Therapeutics study
The first cohort has been successfully dosed in the Phase 1, single ascending dose study to explore the pharmacokinetics and safety and tolerability of subcutaneous sevuparin injections in healthy volunteers (HV). This study complements a large Phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. “This Phase 1 study […]
In a new job - February 1, 2019
Modus Therapeutics appoints two new Board members
Modus Therapeutics strengthens its Board of Directors with two key appointments, Stig Løkke Pedersen and Karin Knobe. Stig Løkke Pedersen, an experienced life science industry veteran with more than 30 years’ experience, has been appointed Chairman of the Board. Mr Løkke Pedersen worked for 20 years at H. Lundbeck A/S, and served as the Group’s Chief […]
Clinical Trials - January 7, 2019
Modus Therapeutics completes enrollment of Phase II study
The company announces that it has completed patient enrollment in its multi-centre, Phase II, randomized, double-blind, placebo-controlled study to explore the efficacy and safety of Sevuparin infusion for the management of Acute Vaso-Occlusive Crisis (VOC) in patients with sickle cell disease. This large, expanded, global Phase II study recruited over 140 patients at clinical sites across […]
In a new job - March 15, 2018
Modus Therapeutics appoints new CMO
The company has appointed Dr. John Öhd as the Company’s Chief Medical Officer (CMO). Öhd joins Modus from Medivir, where he was CMO and a member of the company’s Executive Management team. Before taking up his current position, John was Medivir’s Director of Clinical R&D. Prior to joining Medivir, John was senior director of Experimental Medicine at Shire […]
